BR0313965A - Compostos antiiflamatórios di e triflúor-triazolo-piridinas - Google Patents
Compostos antiiflamatórios di e triflúor-triazolo-piridinasInfo
- Publication number
- BR0313965A BR0313965A BR0313965-4A BR0313965A BR0313965A BR 0313965 A BR0313965 A BR 0313965A BR 0313965 A BR0313965 A BR 0313965A BR 0313965 A BR0313965 A BR 0313965A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- triazolo
- alpyridine
- oxazol
- difluoro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- AIUXSZUEIAKPML-UHFFFAOYSA-N 5,6,7-trifluoro-2h-triazolo[4,5-b]pyridine Chemical compound FC1=C(F)C(F)=NC2=C1NN=N2 AIUXSZUEIAKPML-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 abstract 1
- -1 3,4-Difluoro-phenyl Chemical group 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000008523 triazolopyridines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
Abstract
"COMPOSTOS ANTIINFLAMATóRIOS DI E TRIFLúOR-TRIAZOLO-PIRIDINAS". A presente invenção refere-se a novas triazolo-piridinas de fórmula (I) em que R^ 1^ é flúor; s é um número inteiro desde dois até três; R^ 2^ é (C3-C6)cicloalquila opcionalmente substituída por uma ou duas porções seleccionadas independentemente do grupo consistindo em halo, (C~ 1~-C~ 4~)alquila, hidróxi, (C~ 1~-C~ 6~)alcóxi e (C~ 1~-C~ 6~)alquil-(C=O)-O-; ou R^ 2^ é (C~ 1-C~ 6~)alquila opcionalmente substituída por uma ou duas porções seleccionadas independentemente do grupo consistindo em halo, (C~ 1~-C~ 6~)alquila, hidróXi, (C~ 1~-C~ 6~)alcóxi e (C~ 1~-C~ 6~)alquil-(C=O)-0-; com a condição de que o composto de fórmula (I) referido não pode ser 6-[4-(2,4-Difluoro-fenil)-oxazol-5il]-3-isopropil-[1,2,4]triazolo[4,3-alpirid ina; ou 6-[4-(3,4-Difluoro-fenil)-oxazol-5-il]-3-isopropil-[1,2,4]triazolo[4,3-alpiri dina; com intermediários para a sua preparação, com formulações farmacêuticas contendo-as e com as suas utilizações clínicas. Os compostos da presente invenção são potentes inibidores das cinases MAP, preferencialmente cinase p38. São úteis no tratamento da inflamação, osteoartrite, artrite reumatóide, câncer, reperfusão ou isquêmia em acidente vascular cerebral ou enfarte do miocárdio, doenças auto-imunes e outros distúrbios.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40717702P | 2002-08-30 | 2002-08-30 | |
| PCT/IB2003/003847 WO2004020440A1 (en) | 2002-08-30 | 2003-08-19 | Di and trifluoro-triazolo-pyridines anti-inflammatory compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313965A true BR0313965A (pt) | 2005-07-19 |
Family
ID=31978432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313965-4A BR0313965A (pt) | 2002-08-30 | 2003-08-19 | Compostos antiiflamatórios di e triflúor-triazolo-piridinas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7259171B2 (pt) |
| EP (1) | EP1537108B1 (pt) |
| JP (1) | JP2006504680A (pt) |
| AR (1) | AR041078A1 (pt) |
| AT (1) | ATE414705T1 (pt) |
| AU (1) | AU2003259438A1 (pt) |
| BR (1) | BR0313965A (pt) |
| CA (1) | CA2494754A1 (pt) |
| DE (1) | DE60324806D1 (pt) |
| ES (1) | ES2315560T3 (pt) |
| GT (1) | GT200300187A (pt) |
| MX (1) | MXPA05002304A (pt) |
| PA (1) | PA8579601A1 (pt) |
| PE (1) | PE20040978A1 (pt) |
| TW (1) | TW200420562A (pt) |
| UY (1) | UY27961A1 (pt) |
| WO (1) | WO2004020440A1 (pt) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006517580A (ja) * | 2003-02-14 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗炎症化合物としてのトリアゾロピリジン |
| US20090215817A1 (en) * | 2004-08-18 | 2009-08-27 | Pfizer Inc | Novel Triazolopyridine Compounds for the Treatment of Inflammation |
| ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
| ATE542818T1 (de) * | 2006-10-11 | 2012-02-15 | Amgen Inc | Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| ES2329639B1 (es) | 2007-04-26 | 2010-09-23 | Laboratorios Almirall S.A. | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| PT2464645T (pt) | 2009-07-27 | 2017-10-11 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de iões |
| EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
| WO2012003392A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| AU2012253653A1 (en) | 2011-05-10 | 2013-05-02 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (pt) | 2011-07-01 | 2018-04-28 | ||
| CA2879431A1 (en) | 2012-07-17 | 2014-01-23 | Washington University | Anti-mucus drugs and uses therefor |
| EP3521284B1 (en) | 2013-03-15 | 2020-12-02 | The Trustees of Columbia University in the City of New York | Pyrazine compounds as map kinase modulators and uses thereof |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| WO2019071144A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CN109867617A (zh) * | 2019-04-03 | 2019-06-11 | 南京格亚医药科技有限公司 | 一种4-甲氧基吡咯中间体的制备方法 |
| WO2024052684A1 (en) | 2022-09-09 | 2024-03-14 | MyricX Pharma Limited | Antibody drug conjugate comprising nmt inhibitor and its use |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716972A (en) * | 1993-01-13 | 1998-02-10 | Smithkline Beecham Corporation | Pyridyl substituted imidazoles |
| AU686669B2 (en) * | 1993-09-17 | 1998-02-12 | Smithkline Beecham Corporation | Drug binding protein |
| JPH09505055A (ja) * | 1993-11-08 | 1997-05-20 | スミスクライン・ビーチャム・コーポレイション | サイトカイン媒介疾患治療用オキサゾール |
| US5717100A (en) * | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| ZA97175B (en) * | 1996-01-11 | 1997-11-04 | Smithkline Beecham Corp | Novel substituted imidazole compounds. |
| TR199801361T2 (xx) * | 1996-01-11 | 1998-10-21 | Smithkline Beecham Corporation | Yeni ikameli imidazol bile�imleri. |
| GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
| EP1082320A4 (en) | 1998-05-26 | 2001-11-21 | Smithkline Beecham Corp | NEW SUBSTITUTED IMIDAZOLE COMPOUNDS |
| US6207687B1 (en) | 1998-07-31 | 2001-03-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| US6350744B1 (en) | 1998-11-20 | 2002-02-26 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
| ES2188280T3 (es) | 1998-12-16 | 2003-06-16 | Aventis Pharma Ltd | Acetales heteroaril-ciclicos. |
| JP2002534385A (ja) | 1999-01-08 | 2002-10-15 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
| EP1370557B1 (en) | 2001-03-09 | 2005-11-16 | Pfizer Products Inc. | Benzimidazole anti-inflammatory compounds |
| IL156567A0 (en) * | 2001-03-09 | 2004-01-04 | Pfizer Prod Inc | Triazolopyridines as anti-inflammatory agents |
| EP1247810B1 (en) | 2001-04-04 | 2005-09-07 | Pfizer Products Inc. | Novel benzotriazoles anti-inflammatory compounds |
-
2003
- 2003-08-05 PA PA20038579601A patent/PA8579601A1/es unknown
- 2003-08-19 BR BR0313965-4A patent/BR0313965A/pt not_active IP Right Cessation
- 2003-08-19 JP JP2004532622A patent/JP2006504680A/ja not_active Withdrawn
- 2003-08-19 MX MXPA05002304A patent/MXPA05002304A/es active IP Right Grant
- 2003-08-19 EP EP03791145A patent/EP1537108B1/en not_active Expired - Lifetime
- 2003-08-19 AU AU2003259438A patent/AU2003259438A1/en not_active Abandoned
- 2003-08-19 DE DE60324806T patent/DE60324806D1/de not_active Expired - Lifetime
- 2003-08-19 CA CA002494754A patent/CA2494754A1/en not_active Abandoned
- 2003-08-19 ES ES03791145T patent/ES2315560T3/es not_active Expired - Lifetime
- 2003-08-19 AT AT03791145T patent/ATE414705T1/de not_active IP Right Cessation
- 2003-08-19 WO PCT/IB2003/003847 patent/WO2004020440A1/en not_active Ceased
- 2003-08-25 PE PE2003000863A patent/PE20040978A1/es not_active Application Discontinuation
- 2003-08-27 US US10/649,236 patent/US7259171B2/en not_active Expired - Fee Related
- 2003-08-28 AR ARP030103118A patent/AR041078A1/es unknown
- 2003-08-29 UY UY27961A patent/UY27961A1/es not_active Application Discontinuation
- 2003-08-29 GT GT200300187A patent/GT200300187A/es unknown
- 2003-08-29 TW TW092123952A patent/TW200420562A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200420562A (en) | 2004-10-16 |
| EP1537108B1 (en) | 2008-11-19 |
| AR041078A1 (es) | 2005-04-27 |
| MXPA05002304A (es) | 2005-06-08 |
| US20040053958A1 (en) | 2004-03-18 |
| UY27961A1 (es) | 2004-03-31 |
| EP1537108A1 (en) | 2005-06-08 |
| US7259171B2 (en) | 2007-08-21 |
| CA2494754A1 (en) | 2004-03-11 |
| DE60324806D1 (de) | 2009-01-02 |
| ES2315560T3 (es) | 2009-04-01 |
| ATE414705T1 (de) | 2008-12-15 |
| PA8579601A1 (es) | 2004-05-07 |
| PE20040978A1 (es) | 2004-12-28 |
| JP2006504680A (ja) | 2006-02-09 |
| AU2003259438A1 (en) | 2004-03-19 |
| GT200300187A (es) | 2004-06-23 |
| WO2004020440A1 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7648828B2 (ja) | Ｈｉｆ－２アルファの阻害剤としてのテトラリン化合物及びテトラヒドロキノリン化合物 | |
| TW200420562A (en) | Di and trifluoro-triazolo-pyridines anti-inflammatory compounds | |
| US10875837B2 (en) | Inhibitors of the fibroblast growth factor receptor | |
| EP3707126B1 (en) | Ire1 small molecule inhibitors | |
| MA59373B1 (fr) | [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2 | |
| JP2025514185A (ja) | 三環式ピリドン及びピリミドン | |
| EP3294713B1 (en) | Substituted tetrahydroquinolinone compounds as ror gamma modulators | |
| BR0201087A (pt) | Compostos antiinflamatórios de benzotriazol | |
| EP3145512B1 (en) | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | |
| CA2440222A1 (en) | Triazolopyridines as anti-inflammatory agents | |
| CN117580826A (zh) | Nlrp3炎症小体抑制剂 | |
| KR20170103838A (ko) | 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제 | |
| DOP2002000349A (es) | Nuevos compuestos antiinflamatorios de bencimidazol | |
| NO20076460L (no) | Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav | |
| NZ591712A (en) | Imidazopyridazinecarbonitriles useful as kinase inhibitors | |
| WO2012054332A1 (en) | Substituted hydroxamic acids and uses thereof | |
| WO2007058832A3 (en) | Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors | |
| KR20020030791A (ko) | ｃ－ＪＵＮ Ｎ-말단 키나제(ＪＮＫ) 및 기타의 단백질키나제 억제제 | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| KR20240075952A (ko) | Fgfr 억제제 및 이의 사용 방법 | |
| US12404253B2 (en) | 2,4,6-trisubstituted 1,3,5-triazines as modulators of CX3CR1 | |
| BR0313961A (pt) | Processos e intermediários para preparar triazolo-piridinas | |
| NO20082054L (no) | Nye 2-fenylimidazo[4,5-b]pyridinderivater som inhibitorer av glykogensyntasekinase for behandling av demens og neurodegenerative forstyrrelser | |
| JP2022502438A (ja) | Ｆｇｆｒ４阻害剤及びその使用 | |
| TWI780049B (zh) | 皮膚病變的治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8AANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011. |